Garth Terry, MD, PhD

Personal Statement

My research interests cover two main areas: 1) development and use of novel radioligands for positron emission tomography (PET) in CNS disorders 2) cannabinoid pharmacology, and cannabis use disorder and comorbid neuropsychiatric disorders My VA Career Development Award (VA equivalent of an NIH K-award) focuses on the translational development of imaging neuroinflammation with PET following repetitive blast mild traumatic brain injury (mTBI). In collaboration with David Cook’s lab, imaging neuroinflammation in a mouse model of repetitive mTBI provides an opportunity to compare imaging outcomes directly with histopathology in brain tissue, which is not possible in humans. In collaboration with Elaine Peskind, imaging neuroinflammation in Veterans with mTBI and persistent post-concussive symptoms provides neuroanatomical specificity to ongoing neuroinflammation, which to date has been informed using cerebrospinal fluid and serum biomarkers. To accomplish this, my laboratory evaluates and develops established and novel PET radioligands for biomarkers of neuroinflammation. Additionally, I am interested in developing novel radioligands for druggable targets for which there are no current, suitable radlioligands available. I have several ongoing collaborations with other investigators at UW and VA in which I provide support with PET imaging. As a clinician and researcher, I am interested in how patients use cannabis for perceived therapeutic effect, and the risks and adverse outcomes resulting from substantial or chronic cannabis use. These clinical patterns can now be placed into context with a better understanding of the endocannabinoid system (ECS), which provide opportunity for more selective and safer therapeutic drug development. Due in part to the recentness of discovery of the ECS, one of my goals is to educate clinical providers on the preclinical and evidenced based research conducted to date on cannabis use and the ECS so they are better informed when discussing cannabis use with patients, and better prepared for understanding mechanisms of anticipated ECS-based medications currently under development. A second goal is to conduct research on cannabis use disorder and comorbid conditions, and identification of therapies that might better address a patient’s desired outcome from cannabis use, thereby reducing the likelihood of its associated risks.

Education

MIRECC Research Fellowship, VA Puget Sound Health Care System, 2018
Psychiatry Residency, UCLA, 2015
MD, The George Washington University School of Medicine and Health Sciences, 2011
PhD (clinical neuroscience), Karolinska Institute (in the Graduate Partnership Program with the National Institute of Mental Health), 2009
BS, Haverford College, 2001

Department Affiliations

Other Affiliations

Department of Radiology

Recent Publications

Repetitive Blast Promotes Chronic Aversion to Neutral Cues Encountered in the Peri-Blast Environment.
(2021 Apr 1)
J Neurotrauma 38(7): 940-948
Schindler AG, Terry GE, Wolden-Hanson T, Cline M, Park M, Lee J, Yagi M, Meabon JS, Peskind ER, Raskind MM, Phillips PEM, Cook DG

Chronic elevation of plasma vascular endothelial growth factor-A (VEGF-A) is associated with a history of blast exposure.
(2020 Oct 15)
J Neurol Sci 417(): 117049
Meabon JS, Cook DG, Yagi M, Terry GE, Cross DJ, Muzi M, Pagulayan KF, Logsdon AF, Schindler AG, Ghai V, Wang K, Fallen S, Zhou Y, Kim TK, Lee I, Banks WA, Carlson ES, Mayer C, Hendrickson RC, Raskind MA, Marshall DA, Perl DP, Keene CD, Peskind ER

Blunts versus joints: Cannabis use characteristics and consequences among treatment-seeking adults.
(2019 May 1)
Drug Alcohol Depend 198(): 105-111
Montgomery L, McClure EA, Tomko RL, Sonne SC, Winhusen T, Terry GE, Grossman JT, Gray KM

Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study.
(2018 Nov 1)
Drug Alcohol Depend 192(): 59-66
McClure EA, Baker NL, Sonne SC, Ghitza UE, Tomko RL, Montgomery L, Babalonis S, Terry GE, Gray KM

Evidence for altered brain reactivity to norepinephrine in Veterans with a history of traumatic stress.
(2018 Feb)
Neurobiol Stress 8(): 103-111
Hendrickson RC, Raskind MA, Millard SP, Sikkema C, Terry GE, Pagulayan KF, Li G, Peskind ER

Show complete publication list »
Edit Profile